BCM
RNTX

BIOS Capital Management’s Rein Therapeutics RNTX Stock Holding History

BIOS Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.58M Buy
1,982,375
+291,624
+17% +$362K 4.87% 4
2025
Q4 		$1.96M Hold
1,690,751
– – 2.37% 5
2025
Q3 		$1.94M Hold
1,690,751
– – 2.19% 5
2025
Q2 		$2.37M Hold
1,690,751
– – 3.26% 4
2025
Q1 		$2.99M Hold
1,690,751
– – 3.78% 3
2024
Q4 		$3.89M Buy
+1,690,751
New +$5.12M 4.13% 3

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

BIOS Capital Management's RNTX Position: Q1 2026 in Review

BIOS Capital Management increased its Rein Therapeutics (RNTX) stake by 17% in Q1 2026, buying an estimated $362K and bringing the position to 1,982,375 shares worth $2.58M. The position accounts for 4.87% of the portfolio, ranked #4.

BIOS Capital Management first reported a position in RNTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.89M in Q4 2024. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • BIOS Capital Management held 1,982,375 shares of Rein Therapeutics worth $2.58M as of Q1 2026.
  • BIOS Capital Management bought 291,624 Rein Therapeutics shares in Q1 2026, an estimated $362K.
  • Rein Therapeutics made up 4.87% of BIOS Capital Management's portfolio in Q1 2026, its #4 holding.
  • BIOS Capital Management first reported a position in Rein Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BIOS Capital Management's Rein Therapeutics position peaked at $3.89M in Q4 2024.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on BIOS Capital Management's 13F filing for Q1 2026, filed 13 May 2026.